We are live on ! Find out more
HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares

Delisted

HZNP was delisted on the 5th of October, 2023.

136 hedge funds and large institutions have $1.14B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2014 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

291% more call options, than puts

Call options by funds: $30.3M | Put options by funds: $7.74M

67% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 27

60% more funds holding in top 10

Funds holding in top 10: 58 (+3)

53% more capital invested

Capital invested by funds: $741M → $1.14B (+$396M)

42% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 36

13% more funds holding

Funds holding: 120136 (+16)

Holders
136
Holders Change
+16
Holders Change %
+13.33%
% of All Funds
3.61%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.21%
New
45
Increased
51
Reduced
36
Closed
27
Calls
$30.3M
Puts
$7.74M
Net Calls
+$22.5M
Net Calls Change
-$10.6M

HZNP Hedge Fund Activity: Q4 2014 in Review

136 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2014, worth a combined $1.14B — up 53% from $741M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new HZNP positions and 27 closed out — a net gain of 18 holders — while 51 added to existing stakes and 36 trimmed.

The largest buyer was Deerfield Management, adding an estimated $77.3M. The largest seller was Chartwell Investment Partners, exiting entirely with an estimated $15.8M sold.

  • 136 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2014, up from 120 in Q3 2014.
  • Funds reported $1.14B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2014, up 53% quarter-over-quarter.
  • 45 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2014 and 27 closed out, a net change of +18 holders.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2014 was Deerfield Management, an estimated $77.3M added.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2014 was Chartwell Investment Partners, an estimated $15.8M sold.

Based on aggregated 13F filings for Q4 2014.